Literature DB >> 10955455

The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer.

S Wang1, R V Lloyd, M J Hutzler, M S Safran, N A Patwardhan, A Khan.   

Abstract

Cell cycle progression is facilitated by cyclin-dependent kinases that are activated by cyclins including cyclin D1 and inactivated by cyclin-dependent kinase inhibitors (CDKIs) such as p27. Our previous studies have demonstrated decreased p27 expression in both papillary and more aggressive carcinomas of the thyroid compared to thyroid adenoma and almost similar level of cyclin D1 expression between thyroid adenoma and papillary carcinoma. These results indicate that CDKIs may have an important role in the carcinogenesis of the thyroid and that they probably have a limited role in malignant progression of the thyroid cancer. The role of cyclin D1 in malignant progression of thyroid carcinoma has yet to be established. We studied the expression of cyclin D1 by immunohistochemistry in 34 cases of conventional papillary carcinoma (CPC), 10 cases of minimally invasive follicular carcinoma (MIFC), and 32 cases of more aggressive thyroid carcinoma (ATC), which included 11 tall cell variants, one columnar cell variant of papillary carcinoma, seven insular carcinomas, and 13 anaplastic carcinomas. Cyclin D1 staining was classified by staining score as 0, negative; 1+, less than 25%; 2+, 25 to 50%; and 3+, more than 50% tumor cells staining positive. Kruskal-Wallis one-way ANOVA and Wilcoxon Rank Sum/Mann-Whitney U Test was used to assess the difference in the expression of cyclin D1 between the study groups. Twenty-eight out of the 34 CPCs were cyclin D1 positive, 24 (70%) were 1+, 3 (9%) were 2+, and one (3%) were 3+ positive. Seven of 10 MIFCs were cyclin D1 positive, five (71%) were 1+, and the remaining two (29%) were 2+ positive. On the other hand, 28 of 32 ATCs showed cyclin D1 immunostaining. Of these, three (9%) were 1+, five (13%) were 2+, and 20 (63%) were 3+ positive. This study demonstrates a significant overexpression of cyclin D1 in ATC compared CPC (P < .001) and MIFC (P < .005), suggesting that the cyclin D1 expression may play a role in tumor progression and may have prognostic significance in thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10955455     DOI: 10.1038/modpathol.3880157

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  31 in total

Review 1.  The potential role of mTOR inhibitors in the treatment of endocrine tumors.

Authors:  S Grozinsky-Glasberg; I Shimon
Journal:  J Endocrinol Invest       Date:  2010-05-05       Impact factor: 4.256

2.  Earthworms as agents for ecotoxicity in roxarsone-contaminated soil ecosystem: a modeling study of ultrastructure and proteomics.

Authors:  Ruizi Guo; Xueyao Ding; Wenguang Xiong; Xiaoxia Zhong; Wenfei Liang; Shangji Gao; Mei Hong; Yongxue Sun
Journal:  Environ Sci Pollut Res Int       Date:  2015-04-24       Impact factor: 4.223

3.  Genome-wide appraisal of thyroid cancer progression.

Authors:  Volkert B Wreesmann; Ronald A Ghossein; Snehal G Patel; Charles P Harris; Erik A Schnaser; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Pulivarthi H Rao; Bhuvanesh Singh
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 4.  PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.

Authors:  Gloria Irene Manfredi; Alessandra Dicitore; Germano Gaudenzi; Michele Caraglia; Luca Persani; Giovanni Vitale
Journal:  Endocrine       Date:  2014-08-13       Impact factor: 3.633

5.  Low level of cyclin D1 protein expression in thyroid microcarcinomas from an autopsy series.

Authors:  Gabor Laszlo Kovacs; Eva Stelkovics; Laszlo Krenacs; Gabor Gonda; Miklos Goth; Laszlo Kovacs; Zoltan Gorombey; Erika Hubina; Istvan Szabolcs
Journal:  Endocrine       Date:  2005-02       Impact factor: 3.633

Review 6.  Occult thyroid carcinoma.

Authors:  J Boucek; J Kastner; J Skrivan; E Grosso; B Gibelli; G Giugliano; J Betka
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-12       Impact factor: 2.124

7.  Aberrant expression pattern and location of cullin 1 are associated with the development of papillary carcinoma in thyroid and cyclin D1 expression.

Authors:  Sung-Im Do; Kyungeun Kim; Hyunjoo Lee; Hyun-Soo Kim; Tae Gu Do; Jisup Yun; Dong-Hoon Kim; Seoung Wan Chae; Yong Lai Park; Chan Heun Park; Jin Hee Sohn; Kyueng-Whan Min; Jung-Soo Pyo
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

8.  Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.

Authors:  Magdalena Slosar; Poonam Vohra; Manju Prasad; Andrew Fischer; Robert Quinlan; Ashraf Khan
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

Review 9.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

10.  Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis.

Authors:  A Gasbarri; S Sciacchitano; A Marasco; M Papotti; A Di Napoli; A Marzullo; P Yushkov; L Ruco; A Bartolazzi
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.